Cue Biopharma Inc (CUE)

$1.74 0.10 (6.10%)

16:00 EDT CUE Stock Quote Delayed 30 Minutes

CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 9, 2024

CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023

CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

3 Biotech Stocks to Buy as Companies Ink Major Deals

More Articles

Volume:

Previous Close -

Market Cap 78.23M

PE Ratio -6.00

EPS -0.29

Volume (Avg. Vol.) 278,368

Day's Range $1.63 - $1.86

52-Week Range $1.30 - $4.89

Dividend & Yield N/A (N/A)

CUE Stock Predictions, Articles, and Cue Biopharma Inc News

From InvestorPlace
From the Web

3 Biotech Stocks Sitting on Huge-Upside Catalysts

By Ian Cooper, InvestorPlace Contributor May 26, 2023

The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks.

7 Hot Growth Stocks Poised to Triple in 2023

By Alex Sirois, InvestorPlace Contributor May 5, 2023

These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.

7 High-Potential Penny Stocks in the Biotech Sector

By Ian Cooper, InvestorPlace Contributor May 4, 2023

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Oct 24, 2022

Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning!

Market Update: The 10 Most Volatile Stocks Today

By William White, InvestorPlace Writer May 10, 2021

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day.

7 Stocks With Insider Buying This Week Worth A Look

By Mark Putrino, CMT Jan 29, 2021

Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.

3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston Scientific

By James Brumley, InvestorPlace Feature Writer Jan 7, 2019

The stock charts of GPS, CNP and BSX are set to get the new trading week started on a narrow path. Here's what to watch.

Cue biopharma names

From Seeking Alpha Jan 23, 2023

Cue Biopharma (CUE) promotes its senior Vice President of clinical development, Matteo Levisetti, M.D., to Chief Medical Officer effective January 17, 2023

JMP Securities Reaffirms Their Buy Rating on Cue Biopharma (CUE)

From TipRanks Nov 21, 2022

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Cue Biopharma (CUE – Research Report) today and set a price target of $15.00. The company&#821...

JMP Securities Sticks to Their Buy Rating for Cue Biopharma (CUE)

From TipRanks Aug 24, 2022

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Cue Biopharma (CUE – Research Report) today and set a price target of $15.00. The company&#821...

Stifel Nicolaus Keeps Their Buy Rating on Cue Biopharma (CUE)

From TipRanks Aug 12, 2022

In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $...

JMP Securities Thinks Cue Biopharma’s Stock is Going to Recover

From TipRanks Jun 8, 2022

JMP Securities analyst Reni Benjamin

FDA Accepts IND for Cue Biopharma's CUE-102 in the treatment of Wilms' Tumor 1 (WT1)

From Benzinga May 11, 2022

Cue Biopharma, Inc. (NASDAQ: CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.

ADVERTISEMENT